SCHEMBL6663199

SCHEMBL6663199

Cc1cc([N+](=O)[O-])cc(Cl)c1Oc1ccc(OCOCC[Si](C)(C)C)c(COc2ccc(F)cc2)c1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR4 O95977 3/20 0.35
MAPT P10636 6/20 0.33
LMNA P02545 4/20 0.33
SMN1; SMN2 Q16637 3/20 0.33
HSPB1 P04792 3/20 0.33
HPGD P15428 2/20 0.33
ALDH1A1 P00352 5/20 0.33
KMT2A Q03164 3/20 0.33
MEN1 O00255 2/20 0.33
GAA P10253 1/20 0.33
RAB9A P51151 2/20 0.32
NPC1 O15118 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
EGFR P00533 1/20 0.32
ERBB2 P04626 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6679405 0.87 KMT2A (0.40) S1PR4MAPTLMNASMN1; SMN2HPGD
SCHEMBL6658711 0.83 MAPT (0.39) S1PR4MAPTLMNASMN1; SMN2HPGD
SCHEMBL6661827 0.80 THRA (0.40) MAPTSMN1; SMN2HSPB1KMT2AMEN1
SCHEMBL15508874 0.72 RAB9A (0.55) S1PR4MAPTLMNASMN1; SMN2HPGD
SCHEMBL15508768 0.71 ALDH1A1 (0.44) S1PR4MAPTLMNASMN1; SMN2HPGD
SCHEMBL27247652 0.68 RAB9A (0.44) MAPTLMNASMN1; SMN2HPGDALDH1A1
SCHEMBL8892137 0.68 MAPT (0.43) MAPTLMNASMN1; SMN2HSPB1HPGD
SCHEMBL28730654 0.67 MAPT (0.35) MAPTLMNASMN1; SMN2ALDH1A1KMT2A
SCHEMBL29612490 0.67 MAPT (0.35) MAPTLMNASMN1; SMN2ALDH1A1KMT2A
SCHEMBL10424845 0.67 MEN1 (0.46) MAPTLMNASMN1; SMN2ALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1157001-B1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS PFIZER PROD INC (US) 2004-08-04 EP disclosed
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2003-06-19 US disclosed
US-6545018-B2 Treating obesity, hyperlipidemia, glaucoma, arrhythmia, skin disorders, thyroid disease, hypothyroidism, diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, hypercholesteremia, depression and osteoporosis PFIZER INC. 2003-04-08 US disclosed
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands CHIANG YUAN-CHING PHOEBE (US) 2002-04-25 US disclosed
US-6326398-B1 Oxamic acids and derivatives as thyroid receptor ligands PFIZER INC. 2001-12-04 US disclosed
EP-1157001-A1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS Pfizer Products Inc. (US) 2001-11-28 EP disclosed
WO-2000051971-A1 OXAMIC ACIDS AND DERIVATIVES AS THYROID RECEPTOR LIGANDS PFIZER PRODUCTS INC. (US) 2000-09-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114521-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, TSHR S1PR4 579/4885MAPT 2992/4885LMNA 3196/4885
US-20020049226-A1 Oxamic acids and derivatives as thyroid receptor ligands OXER1, THRA, OXGR1 S1PR4 915/4885MAPT 2875/4885LMNA 3176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.